India's Cipla Unwraps Its Biosimilars Ambitions With A Presence In India And Shanghai; Earmarks $65 Million In First Push
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Many months after keeping its biosimilars plans under wraps, Cipla - India's second-largest drug maker - shared some parts of its proposed big picture that revolves around a manufacturing site in Goa, India, and another firm in Hong Kong that is putting up a biologics manufacturing facility in Shanghai
You may also be interested in...
India’s Cipla Partially Exits Desano Of China; Redeploys Funds Into Biosimilars, APIs
The Indian drug maker has embarked on a new China strategy that includes biosimilars.
Merck, Cipla Deny Deal Talks But The Charm Of The Indian Market Stokes Speculations
MUMBAI - Merck CEO designate Kenneth Frazier's visit to India accompanied by key global leaders earlier this month sparked rumors that takeover of a large Indian company could be on Merck's wish list and Cipla - the largest home-grown company by market share - may be the likely target on the Big Pharma's radar
Merck, Cipla Deny Deal Talks But The Charm Of The Indian Market Stokes Speculations
MUMBAI - Merck CEO designate Kenneth Frazier's visit to India accompanied by key global leaders earlier this month sparked rumors that takeover of a large Indian company could be on Merck's wish list and Cipla - the largest home-grown company by market share - may be the likely target on the Big Pharma's radar